Ultomiris (ravulizumab), an approved infusion therapy for adults with neuromyelitis optica spectrum disorder (NMOSD), is closer to being eligible for reimbursement under public drug plans in Canada, according to its developer, Alexion, AstraZeneca Rare Disease. The company signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA).
News
People diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who lose their jobs or cut back on their hours likely contend with vision loss, worsening pain, the use of walking aids, and frequent fatigue or depressed mood, an international study reports. “Developing a robust set of disability guidelines to protect…
Using noninvasive eye scans may help clinicians to determine if patients — particularly those in early disease stages — have neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), both immune system disorders. That’s according to a review of published studies that together reveal that people with NMOSD…
The infusion therapy Ultomiris (ravulizumab-cwvz) safely and effectively reduces the risk of a relapse in complex cases of neuromyelitis optica spectrum disorder (NMOSD) and may be combined with rituximab for short periods, a case series study shows. For four NMOSD patients at a hospital in Fujiyoshida, Japan, Ultomiris…
Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…
A new artificial intelligence (AI) model that analyzes images of the eye can help accurately identify neuromyelitis optica spectrum disorder (NMOSD), a study shows. The model outperformed specialists when relying solely on eye images. When clinical data such as MRI scans and antibody tests were provided, the model’s accuracy…
Most people with neuromyelitis optica spectrum disorder (NMOSD) have impaired sleep quality and architecture — an individual’s cyclical sleep pattern, involving different stages — relative to healthy people, according to a new study from researchers in India. NMOSD patients were also found to have reductions in the volume of…
People with neuromyelitis optica spectrum disorder (NMOSD) are at a nine times higher risk of developing autoimmune rheumatic diseases, or those affecting the joints, muscles, or connective tissue, a South Korean study found. Connective tissue provides support, connection, and binding for tissues and organs. The findings align with a…
High levels of two proteins, called FAM3B and PF4V1, are associated with a reduced risk of neuromyelitis optica spectrum disorder (NMOSD), while elevated levels of two other proteins, called CLEC11A and SERPINA1, are linked to increased odds of developing the immune system disease. These are the findings of a…
Rituximab and mycophenolate mofetil (MMF) may be the most effective off-label options for neuromyelitis optica spectrum disorder (NMOSD) patients who are unable to access approved therapies, often due to high costs or limited availability, according to a study in China. The study compared the safety and efficacy of four immunosuppressive…
Recent Posts
- The pain of NMOSD nerve sensitivity means more than just a cold shoulder
- Most adults with NMOSD use biologic therapies: Registry study
- Every time I turn to Dr. Google, I get an immune system mystery
- Conventional NMOSD treatment effective in double-negative cases
- Grieving how NMOSD has left me uncomfortable in my own skin
- Enspryng outperforms standard immunosuppressants in NMOSD study
- Slow and steady: I’m ditching big resolutions and easing into a new year
- Late-onset NMOSD responds better to newer, highly effective therapies
- New biomarker may help gauge disease severity in NMOSD
- The longest night of the year offers hope of brighter days with NMOSD